Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Selective delipidation of Mycobacterium bovis BCG retains antitumor efficacy against non-muscle invasive bladder cancer

Cancer Immunology Immunotherapy(2022)10.1007/s00262-022-03236-ySource: DataRank Database

Selective delipidation of Mycobacterium bovis BCG retains antitumor efficacy against non-muscle invasive bladder cancer is a research paper published in Cancer Immunology Immunotherapy (2022). On theSindex it has a DataRank of 0.330. It has been cited 8 times.

N/A

0.330DataRank · unranked

Scored on demand from live citation data

Open Access8 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (13 grants)OA: greenTopics (23)IDs (PubMed, PMC)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.330

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (11)

Meijun Long,Andreu Garcia‐Vilanova ORCID,Russell Ault ORCID,Juan I. Moliva ORCID,Kizil A. Yusoof ORCID

Live enrichment

PubMed:35748904 PMC:PMC10992592

San Antonio Medical Foundation

Grant: SAMF 2019 Fund

The Glenda and Gary Woods Foundation

Grant: Distinguished Chair in GU Oncology

National Institutes of Health

Grant: 8KL2 TR000118

National Institutes of Health

Grant: K23

The Mays Family Cancer Center at University of Texas Health San Antonio

Grant: P30 CA054174

The Roger L. and Laura D. Zeller Charitable Foundation

Grant: Chair in Urologic Cancer

Congressionally Directed Medical Research Programs

Grant: CA170270/P1P2

Bladder Cancer Advocacy Network

Grant: 2016 Young Investigator Award

Cancer Prevention and Research Institute of Texas

Grant: RP170345

NCATS NIH HHS

Grant: KL2 TR000118

National Institutes of Health

Grant: 3KL2TR000118-05S1

Institute for Integration of Medicine & Science: A Partnership to Improve Health

National Institutes of Health

Grant: 5P30CA054174-16

SAN ANTONIO CANCER INSTITUTE

Max and Minnie Tomerlin Voelcker Fund

greenLicense: Springer Nature TDM

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/10992592

publisherhttps://link.springer.com/content/pdf/10.1007/s00262-022-03236-y.pdf

publisherhttps://link.springer.com/article/10.1007/s00262-022-03236-y/fulltext.html

https://doi.org/10.1007/s00262-022-03236-y

https://pubmed.ncbi.nlm.nih.gov/35748904

Fields of Study

0301 basic medicine03 medical and health sciences0302 clinical medicine

MeSH Terms

AnimalsHumansMiceMycobacterium bovisBCG VaccineCytokinesUrinary Bladder NeoplasmsNon-Muscle Invasive Bladder Neoplasms

Keywords

BCGTreatmentBladder cancerDelipidationMiceUrinary Bladder NeoplasmsBCG VaccineHumansAnimalsCytokinesMycobacterium bovisNon-Muscle Invasive Bladder Neoplasms

Sustainable Development Goals

SDG 3: 3. Good health

Selective delipidation of Mycobacterium bovis BCG retains antitumor efficacy against non-muscle invasive bladder cancer

FAIR Checklist

DataRank Breakdown

Authors (11)

Funding (13 grants)

Open Access

Topics

Annotations (Europe PMC)